/ /

Advances

Five things to know about Trump’s FDA lead pick GottliebOn March 10, the White House announced that President Donald Trump selected Scott Gottlieb, MD, who has worked for FDA in the past, as his choice to head the FDA. Here are five things managed healthcare executives should know about the pick.
FDA Approves Drug for Treatment of Nocturnal PolyuriaNoctiva is the first agent approved to temporarily decrease urine production in adults with nocturia from various causes.
Brodalumab approved for psoriasisDr. Mark Lebwohl talks about the FDA’s approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.
Once-daily diabetes drug approvedFDA approved 10 mg dapagliflozin and 5 mg saxagliptin (Qtern, AstraZeneca), to treat type 2 diabetes.
Center’s goal: Give skin disease researchers all they needA new research center makes a database of five million human pathology specimens and 22,000 living consented patients, all searchable by diagnoses, as well as cutting edge human analytic techniques available to anyone interested in carrying out translational skin disease research on human cells and tissues.
Literature updates in pediatric dermatologyA recent pediatric allergy study spells out how to safely introduce peanuts to high-risk (and other) children. Another study suggests that melatonin may have immunomodulatory effects in AD.
Popular asthma inhaler now expanded to kidsA leading asthma inhaler will now be available to additional younger asthma patients, after FDA approved Spiriva Respimat (Boehringer Ingelheim) for the long-term, once-daily maintenance treatment of asthma in people age 6 and older.
Psoriasis drug approved with boxed warningA new drug to treat moderate-to-severe plaque psoriasis carries a black box warning that suicidal ideas and behavior, including completed suicides, have occurred in patients during the drug’s clinical trials.
Muscular dystrophy drug launch halts after pricing concernsMarathon Pharmaceuticals is temporarily pausing the launch of its drug to treat a rare form of muscular dystrophy (MD) after concerns over its $89,000 price tag.
New bladder cancer, kidney disease therapies availableFDA recently approved 2 new therapies: an expanded drug indication for locally advanced or metastatic urothelial carcinoma (mUC) and a treatment for secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Poll

View Results